HopeStage
Back to all studies
CompletedNCT00086593

Lamotrigine added to antipsychotics for persistent schizophrenia symptoms

About this titleRead the official source — NCT00086593

This study evaluated the safety and effectiveness of lamotrigine for people with schizophrenia.

Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of lamotrigine for people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Little Rock and 38 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMay 2004
Recruitment status
Completed
Enrollment listed in the registry
209
Sponsor
GlaxoSmithKline
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Canada, United Kingdom
Age range
From 18 Years to 65 Years
Official registry ID
NCT00086593
Official title
Show the full official title

A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of a Flexible Dose of Lamotrigine Compared to Placebo as an Adjunctive Therapy to an Atypical Antipsychotic Agent(s) in Subjects With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock, United States · Garden Grove, United States · Glendale, United States

34 more locations
  • Los Angeles, United States
  • Pico Rivera, United States
  • San Diego, United States
  • Sherman Oaks, United States
  • Coral Springs, United States
  • Maitland, United States
  • Miami, United States
  • North Miami, United States
  • Winter Park, United States
  • Niles, United States
  • Oak Brook, United States
  • Indianapolis, United States
  • Staten Island, United States
  • Nashville, United States
  • Bellaire, United States
  • San Antonio, United States
  • Madison, United States
  • Edmonton, Canada
  • Kelowna, Canada
  • Winnipeg, Canada
  • Miramichi, Canada
  • Dartmouth, Canada
  • Sydney, Canada
  • Burlington, Canada
  • Greater Sudbury, Canada
  • London, Canada
  • Mississauga, Canada
  • Toronto, Canada
  • Windsor, Canada
  • Bedford, United Kingdom
  • Cambridge, United Kingdom
  • Glasgow, United Kingdom
  • Coventry, United Kingdom
  • Hull, United Kingdom

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of lamotrigine for people with schizophrenia.

Who is behind this study?

The study sponsor is GlaxoSmithKline.

Did this study involve medication?

Yes. The study involved medication, including lamotrigine.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies